Molecular biomarkers of colorectal cancer:prognostic and predictive tools for clinical practice

被引:3
作者
Wei-qin JIANG1
机构
关键词
Colorectal cancer; Biomarker; Predictive value; Prognostic value; Chemotherapy; Targeted therapy;
D O I
暂无
中图分类号
R735.34 [];
学科分类号
100214 ;
摘要
Colorectal cancer remains one of the most common types of cancer and leading causes of cancer death worldwide.Although we have made steady progress in chemotherapy and targeted therapy,evidence suggests that the majority of patients undergoing drug therapy experience severe,debilitating,and even lethal adverse drug events which considerably outweigh the benefits.The identification of suitable biomarkers will allow clinicians to deliver the most appropriate drugs to specific patients and spare them ineffective and expensive treatments.Prognostic and predictive biomarkers have been the subjects of many published papers,but few have been widely incorporated into clinical practice.Here,we want to review recent biomarker data related to colorectal cancer,which may have been ready for clinical use.
引用
收藏
页码:663 / 675
页数:13
相关论文
共 16 条
[1]  
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil–oxaliplatin regimen in patients with metastatic colorectal cancer[J] . Maria J Lamas,Goretti Duran,Emilia Balboa,Beatriz Bernardez,Manuel Touris,Yolanda Vidal,Elena Gallardo,Rafael Lopez,Angel Carracedo,Francisco Barros.Pharmacogenomics . 2011 (3)
[2]   Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy [J].
Huang, Ming-Yii ;
Huang, Meng-Lin ;
Chen, Ming-Jenn ;
Lu, Chien-Yu ;
Chen, Chin-Fan ;
Tsai, Pei-Chien ;
Chuang, Shih-Chang ;
Hou, Ming-Feng ;
Lin, Shiu-Ru ;
Wang, Jaw-Yuan .
PHARMACOGENETICS AND GENOMICS, 2011, 21 (01) :18-25
[3]  
Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions[J] . Benoist Chibaudel,Christophe Tournigand,Thierry André,Annette K. Larsen,Aimery Gramont de.Clinical Colorectal Cancer . 2010 (5)
[4]  
Effects of KRAS, BRAF, NRAS , and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis[J] . Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesc
[5]   Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin [J].
Petrioli, Roberto ;
Bargagli, Gianluca ;
Lazzi, Stefano ;
Pascucci, Alessandra ;
Francini, Edoardo ;
Bellan, Cristiana ;
Conca, Raffaele ;
Martellucci, Ignazio ;
Fiaschi, Anna Ida ;
Lorenzi, Bruno ;
Francini, Guido .
ANTI-CANCER DRUGS, 2010, 21 (03) :313-319
[6]  
Skin toxicities of targeted therapies[J] . Siegfried Segaert,Gabriela Chiritescu,Liesbeth Lemmens,Kristien Dumon,Eric Van Cutsem,Sabine Tejpar.European Journal of Cancer . 2009
[7]  
EGFR FISH in colorectal cancer: what is the current reality?[J] . Mauro Moroni,Andrea Sartore-Bianchi,Silvio Veronese,Salvatore Siena.Lancet Oncology . 2008 (5)
[8]  
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patients[J] . Srinivasa RaoJada,RobertLim,Chiung IngWong,XiaochenShu,Soo ChinLee,QingyuZhou,Boon CherGoh,BalramChowbay.Cancer Science . 2007 (9)
[9]  
Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?[J] . Kwang Wook Suh,Joo Hyung Kim,Do Yoon Kim,Young Bae Kim,Chulho Lee,Sungho Choi.Annals of Surgical Oncology . 2006 (11)
[10]   Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue [J].
Hotta, T ;
Taniguchi, K ;
Kobayashi, Y ;
Johata, K ;
Sahara, M ;
Naka, T ;
Watanabe, T ;
Ochiai, M ;
Tanimura, H ;
Tsubota, YT .
ONCOLOGY REPORTS, 2004, 12 (03) :539-541